Faricimab Ophthalmic Dosage

Medically reviewed by Drugs.com. Last updated on Nov 15, 2023.

Usual Adult Dose for Macular Degeneration

6 mg intravitreally every 4 weeks for the first 4 doses, followed by 6 mg intravitreally on:

• Regimen 1: Weeks 28 and 44; OR
• Regimen 2: Weeks 24, 36, and 48; OR
• Regimen 3: Weeks 20, 28, 36, and 44

Comments:

• This drug should be administered every 4 weeks (about every 28 days [plus or minus 7 days], monthly) for the first 4 doses, followed by optical coherence tomography and visual acuity evaluations 8 and 12 weeks later to inform whether to administer the next dose as 1 of 3 regimens.
• Although additional efficacy was not shown in most patients when this drug was dosed every 4 weeks compared to every 8 weeks, some patients may need to be dosed every 4 weeks (monthly) after the first 4 doses.
• No dose adjustment is recommended in patients 65 years or older.
• Patients should be assessed regularly.

Use: For the treatment of patients with neovascular (wet) age-related macular degeneration

Usual Adult Dose for Retinal Disorder

DIABETIC MACULAR EDEMA (DME):
Regimen 1: 6 mg intravitreally every 4 weeks for at least 4 doses

• If edema is resolved after at least 4 doses (based on the central subfield thickness [CST] of the macula as measured by optical coherence tomography), then the dosing interval may be modified by extensions of up to 4-week interval increments or reductions of up to 8-week interval increments based on CST and visual acuity evaluations.

-OR-
Regimen 2: 6 mg intravitreally every 4 weeks for the first 6 doses, followed by 6 mg intravitreally every 8 weeks (2 months)

MACULAR EDEMA FOLLOWING RETINAL VEIN OCCLUSION (RVO): 6 mg intravitreally every 4 weeks for 6 months

Comments:

• This drug should be administered every 4 weeks (about every 28 days [plus or minus 7 days], monthly) for at least 4 doses (DME-regimen 1), for the first 6 doses (DME-regimen 2), or for 6 months (RVO); dosing interval changes should be informed by optical coherence tomography.
• Although additional efficacy was not shown in most patients with DME when this drug was dosed every 4 weeks compared to every 8 weeks, some patients may need dosing every 4 weeks (monthly) after the first 4 doses.
• No dose adjustment is recommended in patients 65 years or older.
• Patients should be assessed regularly.

Use: For the treatment of patients with DME or macular edema following RVO

Usual Adult Dose for Macular Edema

DIABETIC MACULAR EDEMA (DME):
Regimen 1: 6 mg intravitreally every 4 weeks for at least 4 doses

• If edema is resolved after at least 4 doses (based on the central subfield thickness [CST] of the macula as measured by optical coherence tomography), then the dosing interval may be modified by extensions of up to 4-week interval increments or reductions of up to 8-week interval increments based on CST and visual acuity evaluations.

-OR-
Regimen 2: 6 mg intravitreally every 4 weeks for the first 6 doses, followed by 6 mg intravitreally every 8 weeks (2 months)

MACULAR EDEMA FOLLOWING RETINAL VEIN OCCLUSION (RVO): 6 mg intravitreally every 4 weeks for 6 months

Comments:

• This drug should be administered every 4 weeks (about every 28 days [plus or minus 7 days], monthly) for at least 4 doses (DME-regimen 1), for the first 6 doses (DME-regimen 2), or for 6 months (RVO); dosing interval changes should be informed by optical coherence tomography.
• Although additional efficacy was not shown in most patients with DME when this drug was dosed every 4 weeks compared to every 8 weeks, some patients may need dosing every 4 weeks (monthly) after the first 4 doses.
• No dose adjustment is recommended in patients 65 years or older.
• Patients should be assessed regularly.

Use: For the treatment of patients with DME or macular edema following RVO

Renal Dose Adjustments

Mild to severe renal dysfunction (CrCl 15 to 89 mL/min/1.73 m2 [estimated normalized CrCl by Cockcroft-Gault equation]): No adjustment recommended
CrCl less than 15 mL/min/1.73 m2: Data not available

Liver Dose Adjustments

Liver dysfunction: Data not available

Precautions

CONTRAINDICATIONS:

• Ocular or periocular infections
• Active intraocular inflammation
• Known hypersensitivity to the active component or any of the ingredients

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

• For intravitreal injection
• This drug must be administered by a qualified physician.
• Administer immediately after preparation of the dose.
• Each vial or prefilled syringe should only be administered for the treatment of a single eye.

Injection Procedure:

• Prior to injection, review the instructions in the manufacturer product information.
• Perform under aseptic conditions, which includes using surgical hand disinfection, sterile gloves, sterile drape, and sterile eyelid speculum (or equivalent), and sterile paracentesis equipment available (if needed).
• Administer adequate anesthesia and a broad-spectrum microbicide before the injection.
• Inject slowly until the rubber stopper reaches the end of the syringe to deliver 0.05 mL.
• Immediately after intravitreal injection, monitor patients for elevation in intraocular pressure; appropriate monitoring may consist of checking for perfusion of the optic nerve head or tonometry. If required, a sterile paracentesis needle should be available.
• If the contralateral eye requires treatment, use a new syringe and change the sterile field, syringe, gloves, drapes, eyelid speculum, filter, and injection needles before administering this drug to the other eye.
• Assess patients regularly.

Storage requirements:

• Store in refrigerator between 2C to 8C (36F to 46F); do not freeze or shake.
• Keep vial or prefilled syringe in the original carton to protect from light.
• Allow this drug to reach room temperature (20C to 25C [68F to 77F]) before administration; the unopened vial or prefilled syringe may remain at room temperature for up to 24 hours.

Reconstitution/preparation techniques:

• The manufacturer product information should be consulted.

Monitoring:

• Ocular: For elevation in intraocular pressure (immediately after injection); for perfusion of optic nerve head

Patient advice:

• After injection, immediately report any symptoms suggestive of endophthalmitis or retinal detachment (e.g., vision loss, eye pain, redness of the eye, photophobia, burring of vision); in the days after administration, seek immediate care from an ophthalmologist if the eye becomes red, sensitive to light, or painful, or if a change in vision occurs.
• Do not drive or use machinery until visual function has recovered sufficiently.
• Speak to a health care provider if you are pregnant or breastfeeding.

See also:

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer